Drug Profile

KR 335

Alternative Names: KR-335

Latest Information Update: 11 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kernal Biologics
Class Antineoplastics; RNA
Mechanism of Action Protein synthesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

09 Jan 2023 Efficacy and pharmacodynamics data from a preclinical trial in Cancer released by Kernal Biologics
09 Nov 2022 Pharmacodynamics data from preclinical studies in Cancer released by Kernal Biologics
11 Jul 2022 KR 335 is available for licensing as of 11 Jul 2022. https://www.kernalbio.com/partnerships

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com